Support PBS listing for pembrolizumab
6 May 2019
Following the November 2018 PBAC meeting, pembrolizumab has been resubmitted to the Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July 2019 to seek reimbursement on the PBS for the adjuvant treatment of patients with resected stage III melanoma.
Listing on the Australian Pharmaceutical benefits scheme would provide subsidised access to this treatment for resected stage III melanoma.
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
Submissions will be accepted until Wed 12 June 2019, and they can be made as follows:
- Email your input directly to the PBAC at CommentsPBAC@health.gov.au
- Mail your submission to the PBAC Secretariat: MDP 952, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601
- There is also an online portal for submission
Please note that if you are submitting via the online portal, there are two submissions for pembrolizumab. Please select the option that states Indication: Melanoma – the first pembrolizumab option.
Nine practice points from the new melanoma guidelines
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Melanoma under 40
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Don't let sunburn be your summer holiday souvenir
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Using clinical features to identify patients at high risk for melanoma
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Congratulations to Professor Georgina Long
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
Uniting our global researchers for melanoma
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care go digital
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Awards and honours for our talented researchers
Congratulations are in order for two of our talented researchers.
5 Minutes With Prof Richard Scolyer
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Research spotlight: High Risk Clinic
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
Learning from the best in the world
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
Uniting the world for a cure
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
A Day in the Life of... Michelle Peranec
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Wildfire Award helps ignite new melanoma research
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Opinion: Fighting the Resistance
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
5 Minutes With A/Prof Jennifer Wargo
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott awarded for outstanding cancer research
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
Community invests in MIA's new trial
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
New trial giving options
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Melanoma research summary from ASCO
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.